AN2 Therapeutics, Inc. Payments to Acquire Investments
AN2 Therapeutics, Inc. (ANTX) reported Payments to Acquire Investments of $16.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-11
- AN2 Therapeutics, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $13.66M, a 17.09% increase year-over-year.
- AN2 Therapeutics, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $2.70M, a 87.88% decline year-over-year.
- AN2 Therapeutics, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $8.33M, a 65.85% decline year-over-year.
- AN2 Therapeutics, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $3.89M, a 60.23% decline year-over-year.
- AN2 Therapeutics, Inc. payments to acquire investments for fiscal 2025 was $46.19M, a 1.20% decline from fiscal 2024.
- AN2 Therapeutics, Inc. payments to acquire investments for fiscal 2024 was $46.75M, a 64.63% decline from fiscal 2023.
- AN2 Therapeutics, Inc. payments to acquire investments for fiscal 2023 was $132.18M, a 40.86% increase from fiscal 2022.
- AN2 Therapeutics, Inc. payments to acquire investments for fiscal 2022 was $93.84M, a 21.43% increase from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $16.36M 10-Q · filed 2026-08-11 | $24.69M derived: sum of 3 quarters · filed 2026-08-11 | $28.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.70M 10-Q · filed 2026-05-11 | $11.03M derived: sum of 2 quarters · filed 2026-05-11 | $14.92M derived: sum of 3 quarters · filed 2026-05-11 | $26.59M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $8.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $12.22M derived: sum of 2 quarters · filed 2026-03-17 | $23.88M derived: sum of 3 quarters · filed 2026-08-11 | $46.19M 10-K · filed 2026-03-17 |
| 2025-09-30 | $3.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $15.56M derived: sum of 2 quarters · filed 2026-08-11 | $37.86M 10-Q · filed 2025-11-12 | $62.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $11.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $33.97M 10-Q · filed 2026-08-11 | $58.35M derived: sum of 3 quarters · filed 2026-08-11 | $68.13M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $22.31M 10-Q · filed 2026-05-11 | $46.69M derived: sum of 2 quarters · filed 2026-05-11 | $56.47M derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | $24.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $34.16M derived: sum of 2 quarters · filed 2026-03-17 | $46.75M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $9.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $22.37M 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $12.59M 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $19.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $105.04M derived: sum of 2 quarters · filed 2025-03-25 | $118.17M derived: sum of 3 quarters · filed 2025-03-25 | $132.18M 10-K · filed 2025-03-25 |
| 2023-09-30 | $85.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $98.33M derived: sum of 2 quarters · filed 2024-11-13 | $112.35M 10-Q · filed 2024-11-13 | $129.79M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $13.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $27.14M 10-Q · filed 2024-08-13 | $44.58M derived: sum of 3 quarters · filed 2024-08-13 | $66.99M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $14.01M 10-Q · filed 2024-05-14 | $31.46M derived: sum of 2 quarters · filed 2024-05-14 | $53.87M derived: sum of 3 quarters · filed 2024-05-14 | $106.85M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $17.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $39.85M derived: sum of 2 quarters · filed 2024-03-29 | $92.84M derived: sum of 3 quarters · filed 2024-03-29 | $93.84M 10-K · filed 2024-03-29 |
| 2022-09-30 | $22.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $75.39M derived: sum of 2 quarters · filed 2023-11-09 | $76.39M 10-Q · filed 2023-11-09 | $92.39M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $52.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $53.98M 10-Q · filed 2023-08-10 | $69.99M derived: sum of 3 quarters · filed 2023-08-10 | $81.97M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $998.00K 10-Q · filed 2023-05-11 | $17.00M derived: sum of 2 quarters · filed 2023-05-11 | $28.99M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $27.99M derived: sum of 2 quarters · filed 2023-03-29 | $77.27M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $11.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $61.27M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $49.28M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |